Canada-based drug development company Sierra Oncology has acquired Gilead Sciences’ momelotinib, a drug candidate being developed to treat myelofibrosis, in a deal worth up to $198m.
The drug is a potent, selective and orally-bioavailable inhibitor of janus kinase 1 and 2 (JAK1 and JAK2), as well as activin receptor type 1 (ACVR1).
Go deeper with GlobalData
It was discovered and initially developed by Australian biotechnology firm Cytopia, which was acquired by YM BioSciences in 2011. YM BioSciences was later purchased by Gilead in 2013.
Under the terms of the latest agreement, Sierra will make an upfront payment of $3m for Gilead’s momelotinib, followed by additional aggregate milestone payments of up to $195m, based upon commercial sales of the drug.
Gilead will also receive tiered royalties on momelotinib sales.
After the completion of transition period, Sierra will assume responsibility of all ongoing clinical trials of the drug candidate.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSierra Oncology president and CEO Nick Glover said: “Opportunistically adding this compelling phase III asset to our existing pipeline of next generation oncology drug candidates, SRA737 and SRA141, helps establish Sierra as a diversified late-stage drug development company with a commercial orientation.
“The company is uniquely positioned to advance momelotinib towards potential registration with several members of the Sierra senior management team having played key roles in the development of momelotinib from its discovery through to phase III clinical trials.”
To date more than 1,200 patients have been treated with Gilead’s momelotinib since clinical studies commenced in 2009. The drug candidate has been recently evaluated in two Phase III clinical trials.
It was found to have a potentially differentiated therapeutic profile with anaemia-related benefits that included elimination or decrease in the requirement for frequent blood transfusions.
The drugcandidate also demonstrated substantive spleen and constitutional symptom control.
